ArticleBlood advances2022
ABO blood group type and risk of venous thromboembolism in patients with cancer.
Article in Blood advances, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 38 citations in OpenAlex.
- Blood Transfusion and ABO Blood Groups in Sickle Cell Disease.Medicina (Kaunas, Lithuania) · 2026Article
- Gut microbiome signatures discriminate deep vein thrombosis through machine learning and metabolic analysis.Scientific reports · 2026Article
- Insights on management of recurrence of Cancer-associated isolated distal deep vein thrombosis.Journal of thrombosis and thrombolysis · 2026Review
- Prognostic Impact of ABO/Rh Blood Group-Systemic Inflammation Indices Interactions in Small-Cell Lung Cancer.Biomedicines · 2026Article
- Population-specific ABO haplotypes reveal distinct venous thromboembolism risk in East Asians: insights from a large-scale genetic study.The Lancet regional health. Western Pacific · 2026Article
- Proteome-wide Mendelian randomization and colocalization analysis uncovers druggable targets for lung cancer across multiple phenotypes and complications.Discover oncology · 2025Article
- Analysis of risk factors for lower extremity DVT following robot-assisted radical prostatectomy and nursing intervention strategies: a single centre retrospective cohort study.Journal of robotic surgery · 2025Article
- From Circulating Biomarkers to Polymorphic Variants: A Narrative Review of Challenges in Thrombophilia Evaluation.Journal of clinical medicine · 2025Review
- Clonal hematopoiesis in patients with cancer and its association with risk of thrombosis and prognosis of disease.Research and practice in thrombosis and haemostasis · 2025Article
- Additive association of blood group A allele with 15 cardiometabolic diseases: a UK Biobank life-course study.Cardiovascular diabetology · 2025Article
- The association between ABO blood type and outcomes following sudden cardiac arrest: a multicenter observational study.Frontiers in medicine · 2025Article
- ABO blood group and COVID-19 severity: Associations with endothelial and adipocyte activation in critically ill patients.PloS one · 2025Article
- Predictors of amputation in patients with diabetic foot ulcers: a multi-centre retrospective cohort study.Endocrine · 2024Article
- Trends and Updates on the Epidemiology of Cancer Associated Thrombosis: A Systematic Review.Bleeding, thrombosis and vascular biology · 2024Article
- Celebrating a year of cancer research in Blood Advances.Blood advances · 2023Article
- Investigating patients for bleeding disorders when most of the "usual" ones have been ruled out.Research and practice in thrombosis and haemostasis · 2023Article
- Duffy-null erythrocyte phenotype and the risk of thrombotic events in essential thrombocythemia.EJHaem · 2023Article
- Association of ABO blood groups with venous thrombosis recurrence in middle-aged patients: insights from a weighted Cox analysis dedicated to ambispective design.BMC medical research methodology · 2023Article
- Von Willebrand factor in the plasma and in the tumor tissue predicts cancer-associated thrombosis and mortality.Haematologica · 2023Article
- Profile of Solid Tumor Patients Complicated With Venous Thromboembolism: A 10-Year Retrospective Cross-Sectional Study Based on 1482 Cases.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/HemostasisObservational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Venous thromboembolism (VTE) is common in patients with cancer. Although in the general population blood type non-O is associated with increased VTE risk, the impact of ABO blood type on risk of cancer-associated VTE has not been clarified. To determine the influence of ABO blood type on cancer-associated VTE risk, we conducted an analysis within the Vienna Cancer and Thrombosis Study, a prospective cohort study including patients with newly diagnosed or recurrent cancer observed for the primary outcome VTE. Restricted cubic spline analysis was performed and specific time-restricted subdistribution hazard ratios (SHR) were calculated to investigate the association between non-O blood type and VTE over time. One thousand, seven hundred and eight patients were included in the analysis (median follow-up time: 24 months; interquartile range: 10-24), and 151 patients developed VTE (8.8%). During the first 3 months of follow-up, there was no association between non-O blood type and VTE risk (SHR: 1.00; 95% confidence interval [CI]: 0.60-1.67). Thereafter, non-O blood type was associated with a higher VTE risk (SHR: 1.79; 95% CI: 1.12-2.85). Furthermore, non-O blood type was associated with increased VTE risk in patients with intermediate and low thrombotic risk tumor types (SHR: 1.73; 95% CI: 1.09-2.73) but not in very high-risk types (pancreatic, gastroesophageal, and brain cancer; SHR: 0.94; 95% CI: 0.55-1.61). This association was weakened after adjustment for factor VIII. Non-O blood type is a time-dependent predictor of VTE in patients with cancer. It is associated with increased VTE risk beyond 3 months of follow-up and in patients with intermediate- and low-risk tumor types.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.